Patent ID: 6576766
Filing Date: 2003-06-10
Classification: A61K,C07C,C07D,C07F,C07K

Abstract:
A compound of the formula: whereinY is G is â€”Oâ€”, â€”Sâ€” or â€”Nâ€”; R6 comprises â€”APO3RRâ€², â€”OPO3RRâ€², â€”ASO3R, â€”OSO3R, â€”ACO2R, â€”A-tetrazole, â€”ASO2NRRâ€², â€”ACOCF3, â€”C(O)J, â€”C(R)(J)(K) or â€”C(Z)(J)(K); where each occurrence of A is independently a covalent bond, â€”Gâ€”Mâ€” or â€”(M)mâ€”; each occurrence of M is an independently selected, substituted or unsubstituted, methylene moiety, and any Mâ€”Mâ€² moiety may be electronically saturated or unsaturated; each n is independently 0, 1, 2, 3, 4 or 5; each m is independently 0, 1 or 2; J and K are independently â€”APO3RRâ€², â€”OPO3RRâ€², â€”ASO3R, â€”OSO3R, â€”ACO2R, â€”A-tetrazole, â€”ASO2NRRâ€², â€”(M)nâ€”NRRâ€² or â€”(M)nâ€”OR; Z is a halogen; R7 and R8 are independently R, â€”CN, â€”NO2, Z, J, â€”A(M)naliphatic, â€”G(M)naliphatic, â€”(M)nCOR) â€”(M)nOR, â€”(M)nCOOR, â€”Aâ€”(M)nNRRâ€², â€”G(M)qNRRâ€², â€”(M)nCHO, â€”A(M)nN(R)(CO)Râ€², â€”A(M)nN(R)(CO)GRâ€², â€”G(M)nN(R)(CO)Râ€², â€”Gâ€”(M)nN(R)(CO)Gâ€²Râ€², â€”Aâ€”(M)nâ€”COâ€”NRRâ€², or â€”G(M)nâ€”COâ€”NRR, where the aliphatic groups may be substituted or unsubstituted; or R8 is a covalent bond to an R4 substituent of X to form an aliphatic, aryl or heterocyclic ring of 4 to 8 atoms which may be saturated or unsaturated; each occurrence of R (unnumbered) represents hydrogen or an aliphatic, heteroaliphatic, aryl, heteroaryl, (aryl)aliphatic-, or (heteroaryl)aliphatic-moiety, each of which (other than hydrogen) may be substituted or unsubstituted; q is an integer from 1 to 8; R1 is hydrogen, aliphatic, â€”(M)n-cycloaliphatic, â€”(M)n-aryl, or â€”(M)n-heterocyclic, each of which, other than H, may be substituted or unsubstituted; and R2 is hydrogen or substituted or unsubstituted aliphatic; or R1 and R2 are covalently linked together to form a ring; or R1 or R2 are covalently linked to B or a substituent of B to form a 4-0-membered ring (which may be saturated or unsaturated); X is: â€”(CR3R4)mâ€” or â€”NR4â€”; R3 is hydrogen, R(CO)NRâ€²â€”, RRâ€²N(CO)NRâ€³â€”, Râ€²SO2NRâ€”, Râ€²C(S)NRâ€”, RRâ€²NCSNRâ€³â€”, RRâ€²NSO2NRâ€³â€”, Râ€²OCONRâ€”, RRâ€²Nâ€”, or R4 is hydrogen, aliphatic, cycloaliphatic-(M)nâ€”, aryl-(M)nâ€”, heterocyclic-(M)nâ€”, Râ€”SO2Mnâ€”, (ROâ€”CO)(M)nâ€” or (RRâ€²Nâ€”CO)(M)nâ€”, where the aliphatic, cycloaliphatic, aryl or heterocyclic moiety is substituted or unsubstituted; B is where R9, R10 and R11 are independently selected from â€”(M)nR, â€”G(Mn)R, â€”(M)nZ, â€”(M)nCN, â€”(M)nGR, â€”(M)nNRWR, â€”(M)nNRWâ€”GR, â€”(M)nWâ€”R, â€”Gâ€”(M)nWâ€”R, and â€”(M)nWâ€”GR, or R10 and R11 are covalently linked together to form an aliphatic, hetercyclic or aryl fused ring; R12 and R13 are independently selected from the group consisting of hydrogen, aliphatic, heteroaliphatic, aryl, heteroaryl, (aryl)aliphatic-, or (heteroaryl)aliphatic, each of which (other than hydrogen) may be substituted or unsubstituted; or R12 and R13 are covalently linked together to form a heterocyclic moiety; R14 is R; and, U and W are independently â€”COâ€”, â€”CSâ€”, â€”Mâ€”, â€”SOâ€”, or â€”SO2â€”; such that in embodiments in which R6 is (H2O3P)2CHâ€”, R7 and R8 are H, B is â€”C(O)NRRâ€², and X is â€”CHNRâ€”, then R4 is a group other than â€”NHOR where R is H, substituted or unsubstituted benzyl, trialkylsilyl, t butyldiphenylsilyl, tetrahydropyranyl or t-butyl; and in embodiments in which Y is of the structure (a), shown above, where R6 is â€”OPO3RRâ€², â€”CF2PO3RRâ€², â€”CH2PO3RRâ€², â€”SO3R, â€”OSO3R, â€”CH2SO3R, â€”SO2NH2, or â€”CH2SO2NH2; and B is â€”C(O)NRRâ€² or â€ƒwhere R10 is H, Z or alkyl; R11 is H, alkyl, â€”OR, â€”O(CH2)naryl, â€”NRRâ€², â€”O(CH2)n-substituted alkyl, â€”SR, â€”(CH2)n-substituted aryl or â€”(CH2)n-cycloalkyl; and R20 is H, substituted or unsubstituted alkyl, â€”OH or â€”NH2, where the R groups are independently H, alkyl, cycloalkyl â€”(CH2)nâ€”, aryl â€”(CH2)nâ€”, heteroaryl-(CH2)nâ€”, or â€”(CH2)(CH2)nâ€”COOH, where the alkyl, cycloalkyl, aryl and heteroaryl moieties are substituted or unsubstituted, then R7 and R8 are both a moiety other than H or Me, or R7 is a moiety other than Cl; or a pharmaceutically acceptable derivative thereof.